The Sm-TSP-2-based vaccine antigens reported in this study appear to exhibit all the early-stage characteristics of a vaccine targeting developing countries where schistosomiasis is endemic, based on their ease of production, absence of IgE reactivity, preferential recognition by resistant humans [12], essential nature of the protein for parasite survival [16] and vaccine efficacy in animal models. This evidence concerns the gene THBS2 and schistosomiasis.